Sugi Predict

Sugi Predict / Compounds / SCHEMBL789538

SCHEMBL789538

SCHEMBL789538

CC(C)(C)[Si](OCC(=O)O)(c1ccccc1)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 1/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ POLB P06746 1/20 0.40
▸ GLA P06280 1/20 0.40
▸ CYP2C19 P33261 1/20 0.39
▸ HIF1A Q16665 1/20 0.39
▸ PAM P19021 1/20 0.37
▸ CYP3A4 P08684 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ SMYD2 Q9NRG4 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ KCNN4 O15554 1/20 0.35
▸ PTPN7 P35236 1/20 0.35
▸ FFAR1 O14842 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL29015997 1.00 ALOX15 (0.41) ALOX15SMN1; SMN2L3MBTL1POLBGLA
SCHEMBL8354088 0.89 SMYD2 (0.36) ALOX15SMN1; SMN2CYP2C19HIF1ACYP3A4
SCHEMBL7336991 0.88 SMYD2 (0.38) SMN1; SMN2L3MBTL1POLBCYP2C19HIF1A
SCHEMBL25712841 0.86 KDM4E (0.39) SMN1; SMN2L3MBTL1POLBCYP3A4HTT
SCHEMBL4810133 0.86 SMYD2 (0.35) SMN1; SMN2CYP2C19HIF1ACYP3A4HTT
SCHEMBL10828679 0.86 SMYD2 (0.35) ALOX15SMN1; SMN2CYP2C19HIF1ACYP3A4
SCHEMBL13311307 0.85 SMYD2 (0.38) ALOX15SMN1; SMN2L3MBTL1POLBGLA
SCHEMBL7781357 0.85 POLB (0.39) ALOX15SMN1; SMN2L3MBTL1POLBCYP3A4
SCHEMBL26566724 0.85 CYP3A4 (0.37) SMN1; SMN2L3MBTL1GLACYP2C19HIF1A
SCHEMBL8350263 0.85 SMYD2 (0.34) ALOX15SMN1; SMN2CYP2C19HIF1ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108997429-B Method for preparing Beciclovir 广州粤美医药科技有限公司 2020-10-30 — — CN claimed
WO-2026098644-A1 TARGETED PROTEIN DEGRADATION AGENT, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 北京森妙生物科技有限公司 2026-05-15 — — WO disclosed
EP-4653438-A1 MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2025-11-26 — — EP disclosed
US-20250346606-A1 CAMPTOTHECIN COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2025-11-13 — — US disclosed
EP-4634159-A1 SULFOXIMINES AS INHIBITORS OF NAV1.8 Grünenthal GmbH (DE) 2025-10-22 — — EP disclosed
US-12421222-B2 Substituted quinazolines as HDAC6 inhibitors AUGUSTINE THERAPEUTICS (BE) 2025-09-23 — — US disclosed
US-20250281631-A1 ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2025-09-11 — — US disclosed
EP-4601701-A1 ANTIBODY-DRUG CONJUGATE BINDING TO HUMAN PTK7 AND METHOD FOR PREPARATION AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2025-08-20 — — EP disclosed
WO-2025133191-A1 NOVEL SULFONAMIDES OR SULFONES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS GENECODE (EE) 2025-06-26 — — WO disclosed
CN-116867789-B Preparation method of irinotecan derivative and intermediate thereof 上海复旦张江生物医药股份有限公司 2025-06-24 — — CN disclosed
EP-1349843-A1 THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS GLAXO GROUP LIMITED (GB) 2003-10-08 — — EP disclosed
WO-2002059098-A1 THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS GLAXO GROUP LIMITED (GB) 2002-08-01 — — WO disclosed
EP-0188247-B1 PROCESS FOR PREPARING AZETIDINONE INTERMEDIATES FARMITALIA CARLO ERBA S.r.l. (IT) 1991-04-03 — — EP disclosed
EP-0201206-B1 PENEM DERIVATIVES FARMITALIA CARLO ERBA S.r.l. (IT) 1990-07-25 — — EP disclosed
US-4863914-A BACTERICIDES, ANTIBIOTICS FARMITALIA CARLO ERBA (IT) 1989-09-05 — — US disclosed
US-4771134-A Ring-opening process for preparing azetidinone intermediates FARMITALIA CARLO ERBA S.P.A. (IT) 1988-09-13 — — US disclosed
EP-0201206-A1 Penem derivatives FARMITALIA CARLO ERBA S.r.l. (IT) 1986-11-12 — — EP disclosed
EP-0188247-A1 Process for preparing azetidinone intermediates FARMITALIA CARLO ERBA S.r.l. (IT) 1986-07-23 — — EP disclosed
US-4282236-A β-Lactam antibacterial agents, their use in pharmaceutical compositions, and intermediates BEECHAM GROUP LIMITED (GB) 1981-08-04 — — US disclosed
EP-0013067-A1 Bicyclic beta-lactam antibacterial agents, their use in pharmaceutical compositions, processes for their preparation and intermediates for use in such processes BEECHAM GROUP PLC (GB) 1980-07-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346606-A1 CAMPTOTHECIN COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF WEE1, WEE2, PCLAF ALOX15 593/4885SMN1; SMN2 4249/4885L3MBTL1 3364/4885
US-12421222-B2 Substituted quinazolines as HDAC6 inhibitors HDAC6, HDAC9, HDAC1 ALOX15 4253/4885SMN1; SMN2 92/4885L3MBTL1 482/4885
US-20250281631-A1 ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF TOP1, TOP2A, TOP2B ALOX15 4628/4885SMN1; SMN2 4284/4885L3MBTL1 3980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.